

IFW

PATENT

Client Reference Number: P26675CMH:KG

**CERTIFICATE OF HAND DELIVERY**

I hereby certify that this correspondence is being hand filed with the United States Patent and Trademark Office in Washington, DC. 20231

on August 12.2005  
(Date)

Typed or printed name of person signing this certificate

Dr. O.M. (Sam) Zaghmout  
Signature Sam Zaghmout

Attachments: 15 Journal articles and PTO/SB/08 (3 pages).

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants: Antonio FERRANTE**  
**Application Serial Number: 10/505,446**  
**Title: Therapeutic Properties of Oil.**  
**Filing Date: 09/01/2004**  
**Art Unit: 1615**  
**Examiner:**  
**Mail Stop: DD**  
**Document ID No. : 102829877**

Lorton, Virginia. 2005 August 12. Friday.

**INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.56**

Honorable Commissioner of Patents  
P.O.BOX 1450  
Alexandria, VA 222313-1450

Sir:

Submitted herewith on form PTO/SB/08 is a listing of documents known to

Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR

1.56. With the exception of the listed US patents, a copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

---

**Page 1 of 2. 5:16 PM. 8/12/2005. Applicants: Antonio FERRANTE**  
**Application Serial Number: 10/505,446**  
**Title: Therapeutic Properties of Oil.**  
**Filing Date: 09/01/2004**  
**Art Unit: 1615**  
**Examiner:**  
**Mail Stop: DD.**  
**Document ID No. : 102829877**

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR 1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

#### **TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office action on the merits **and thus no certification and/or fee is required.**

#### **RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that listed documents be considered by the Examiner and be made of the record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17 or credit any overpayment, to deposit account No. 50-3321. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, or otherwise


improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-3321.

Respectfully submitted,

By: Sam Zaghmout

O. M. (Sam) Zaghmout Ph.D  
(Registration No. 51,286)

Bio Intellectual Property Service (BIO IPS) LLC  
8509 Kernon Ct, Lorton, VA 22079. USA  
Cell Phone (703-919-4348), Fax: (703-550-0409)  
(703) 550-1968 (Voice/Fax)



Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**(Use as many sheets as necessary)**

Sheet		of	3
-------	--	----	---

**Complete if Known**

Application Number	10/505446
Filing Date	March 3, 2003
First Named Inventor	Antonio FERRANTE
Art Unit	1615
Examiner Name	
Attorney Docket Number	026750M

P26675CM H:K G

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/505,446
Filing Date	09/01/2004
First Named Inventor	Antonio FERRANTE
Art Unit	1615
Examiner Name	
Attorney Docket Number	P26675CMH:KG

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1	WINTER C.A. et al, "Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs", (1962) Proc. Soc. Exp. Biol. Med., Vol. 111, pages 544-547	
	2	SNOWDEN J.M. and WHITEHOUSE M.W., "Anti-inflammatory activity of emu oils in rats", (1997) Journal of Immunopharmacology, Vol. 5, pages 127-132	
	3	HART P.H. et al, "Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes", (2000) Inflammation Research, Vol. 49, pages 619-626	
	4	AZUZU I.U. et al, "The antiinflammatory activity of Icacinia trichantha tuber", (1999) Phytomedicine, Vol. 6(4), pages 267-272	
	5	LOPEZ A. et al, "Effect of emu oil on auricular inflammation induced with croton oil in mice", (1999) Am. J. Vet. Res., Vol. 60 (12), pages 1558-1561	
	6	WHITEHOUSE M.W. et al, "Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine", (1997) Journal of Immunopharmacology, Vol. 6, pages 1-8	
	7	FERRANTE A. et al, "Suppression of the immunological responses in mice by treatment with amphotericin B", (1979) Clin. & Exp. Immunol., Vol. 38, pages 70-76	
	8	COSTABILE M. et al, "A novel long chain polyunsaturated fatty acid, $\beta$ -oxa 21:3n-3, inhibits T lymphocyte proliferation, cytokine production, delayed type hypersensitivity, carrageenan-induced paw oedema reaction and selectively targets intracellular signals", (2001) J. Immunol., Vol. 167, pages 3980-3987	
	9	FLETCHER D. et al, "The influence of the timing of bupivacaine infiltration on the time course of inflammation induced by two carrageenin injections seven days apart", (1997) Pain, Vol. 69, pages 303-309	
	10	FERRANTE A. et al, "Inhibition of mitogen induced human lymphocyte responsiveness by polymyxin antibiotics", (1982) Int. Arch. Allerg. & Appl. Immunol., Vol. 69, pages 279-281	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/505,446		
		Filing Date	09/01/2004		
		First Named Inventor	Antonio FERRANTE		
		Art Unit	1615		
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	P26675CMA:KG

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	11	STAUGAS R.E.M. et al, "Induction of tumour necrosis factor and interleukin -1 by Pseudomonas aeruginosa and exotoxin A-induced suppression of lymphoproliferation, TNF, lymphotoxin, interferon gamma and interleukin -1 in human leukocytes", (1992) Infect. Immun., Vol. 60, pages 3162-3168	
	12	BATES E.J. et al, "Effect of fatty acid structure on neutrophil adhesion, degranulation and damage to endothelial cells", (1995) Atherosclerosis, Vol. 116, pages 247-259	
	13	HUANG Z.H. et al, "Inhibition of stimuli-induced endothelial cell intracellular adhesion molecule -1, E-selectin and vascular cellular adhesion molecule -1 expression by arachidonic acid and its hydroxy- and hydroperoxy-derivatives", (1997) Circulation Research, Vol. 80, pages 149-158	
	14	FERRANTE A. et al, "Neutrophil migration inhibitory properties of polyunsaturated fatty acids: the role of fatty acid structure, metabolism, and possible second messenger systems", (1994) J. Clin. Invest., Vol. 93, pages 1063-1070	
	15	VISIOLI F. and GALLI C., "The effects of minor constituents of olive oil on cardiovascular disease: new findings", (1998) Nutrition Reviews, Vol. 56, pages 142-147	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.